Page last updated: 2024-11-02

pantoprazole and Myositis

pantoprazole has been researched along with Myositis in 1 studies

Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.

Myositis: Inflammation of a muscle or muscle tissue.

Research Excerpts

ExcerptRelevanceReference
"Polymyositis occurring in patients treated with omeprazole has been signalled as a possible adverse drug reaction (ADR) by the New Zealand Intensive Medicines Monitoring Programme (IMMP) and the WHO Collaborating Centre for International Drug Monitoring: the Uppsala Monitoring Centre (UMC)."4.83Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? ( Clark, DW; Strandell, J, 2006)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Clark, DW1
Strandell, J1

Reviews

1 review available for pantoprazole and Myositis

ArticleYear
Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
    European journal of clinical pharmacology, 2006, Volume: 62, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Enzyme Inhibitors;

2006